Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 2/20 | 0.40 |
| ▸ | CMA1 | P23946 | 1/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 2/20 | 0.38 |
| ▸ | TGM2 | P21980 | 1/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 2/20 | 0.36 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ALB | P02768 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25505543 | 0.78 | CREBBP (0.53) | MEN1KMT2A | |
| SCHEMBL25509424 | 0.71 | CREBBP (0.50) | MEN1LMNAKMT2A | |
| SCHEMBL7539674 | 0.68 | TSHR (0.42) | — | |
| SCHEMBL7170205 | 0.68 | BRPF1 (0.59) | AHRCMA1CHEK1CES1TGM2 | |
| SCHEMBL7171052 | 0.68 | BRPF1 (0.59) | AHRCMA1CHEK1CES1TGM2 | |
| SCHEMBL7175133 | 0.68 | BRPF1 (0.59) | AHRCMA1CHEK1CES1TGM2 | |
| SCHEMBL11655854 | 0.68 | HTR2C (0.42) | AHRCMA1CHEK1HTR2CCES1 | |
| SCHEMBL7174569 | 0.67 | KDM4E (0.46) | CHEK1PGRMEN1LMNAKMT2A | |
| SCHEMBL23728608 | 0.67 | KDM4E (0.35) | AHRCMA1CHEK1HTR2CKIF11 | |
| SCHEMBL3964756 | 0.67 | TNKS (0.44) | AHRCMA1CES1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240050576-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2024-02-15 | — | — | US | disclosed |
| US-20230149550-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-05-18 | — | — | US | disclosed |
| US-20230149550-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-05-18 | — | — | US | disclosed |
| CN-115768765-A | Methods and compounds for treating genetic diseases | 设计治疗公司 | 2023-03-07 | — | — | CN | disclosed |
| EP-4100404-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| WO-2021158707-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. (US) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149550-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | DMPK, DTYMK, MYCBP | AHR 3251/4885CMA1 4184/4885CHEK1 811/4885 |
| US-20240050576-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ZFX, GRN, F13B | AHR 2441/4885CMA1 3965/4885CHEK1 2833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.